Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

4.35USD
3:59pm EST
Change (% chg)

$-0.45 (-9.38%)
Prev Close
$4.80
Open
$4.95
Day's High
$4.95
Day's Low
$4.21
Volume
160,010
Avg. Vol
150,601
52-wk High
$14.00
52-wk Low
$4.21

Chart for

About

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $466.41
Shares Outstanding(Mil.): 74.27
Dividend: --
Yield (%): --

Financials

  INSY.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -1.60 -- --
ROI: -195.64 0.60 13.80
ROE: -221.75 -2.18 15.29

New Hampshire physician assistant guilty of Insys opioid kickback scheme

A former physician assistant in New Hampshire was convicted on Tuesday of charges that he accepted nearly $50,000 in kickbacks from Insys Therapeutics Inc in exchange for prescribing its addictive fentanyl spray.

2:46pm EST

New Hampshire physician assistant guilty of Insys opioid kickback scheme

Dec 18 A former physician assistant in New Hampshire was convicted on Tuesday of charges that he accepted nearly $50,000 in kickbacks from Insys Therapeutics Inc in exchange for prescribing its addictive fentanyl spray.

2:44pm EST

Opioid maker Insys paid kickbacks to physician assistant, jury hears

CONCORD, N.H. A former Insys Therapeutics Inc sales representative now married to the drugmaker's ex-CEO said on Wednesday she arranged to have a physician assistant in New Hampshire receive kickbacks to prescribe patients its addictive fentanyl spray.

Dec 12 2018

UPDATE 2-Opioid maker Insys paid kickbacks to physician assistant, jury hears

CONCORD, N.H., Dec 12 A former Insys Therapeutics Inc sales representative now married to the drugmaker's ex-CEO said on Wednesday she arranged to have a physician assistant in New Hampshire receive kickbacks to prescribe patients its addictive fentanyl spray.

Dec 12 2018

Doctor pleads guilty after patient overdoses on Insys-made opioid

A Nevada doctor has pleaded guilty to illegally distributing a fentanyl-based pain spray made by Insys Therapeutics Inc that was meant for cancer patients to a state court judge who did not have the disease and later died of an overdose after using the powerful opioid.

Dec 12 2018

Physician assistant faces U.S. trial over Insys opioid kickbacks

Dec 12 A former physician assistant is set to face trial in New Hampshire on Wednesday over charges he accepted kickbacks from Insys Therapeutics Inc to prescribe a highly addictive fentanyl spray the drugmaker produced.

Dec 12 2018

Former Insys sales director seeks separate opioid bribe trial

A former regional sales director at Insys Therapeutics Inc charged with five other former executives and managers with conspiring to bribe doctors to prescribe an addictive opioid, and set to be tried with them in January, is seeking a separate trial.

Dec 07 2018

Illinois doctor linked to Insys bribe case convicted of fraud

An Illinois doctor who prosecutors say took kickbacks from Insys Therapeutics Inc to prescribe its opioid medication has been convicted on unrelated charges that he defrauded insurers into paying for unperformed chiropractic procedures.

Nov 30 2018

Former Insys executive pleads guilty to opioid bribe scheme

BOSTON A former executive at Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a scheme to bribe doctors to prescribe the company's powerful opioid medication and entered into a deal to cooperate with prosecutors.

Nov 28 2018

UPDATE 3-Former Insys executive pleads guilty to opioid bribe scheme

BOSTON, Nov 28 A former executive at Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a scheme to bribe doctors to prescribe the company's powerful opioid medication and entered into a deal to cooperate with prosecutors.

Nov 28 2018

Earnings vs. Estimates